New trials, publications, preprints and grants on this target, month by month.
Publication
TYK2-Wnt5a Crosstalk in Psoriatic Arthritis: A Hypothesized Immunopharmacological Axis for Inflammation and Structural Remodelling.
8 Oct 2026· Current drug targets· PUBMED
Publication
Safety, pharmacokinetics and pharmacodynamics of ICP-332, an oral TYK2 inhibitor, in healthy participants: a randomized, double-blind, placebo-controlled phase I study.
7 Oct 2026· Frontiers in pharmacology· PUBMED
Trial
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
1 Oct 2026· PHASE2 · RECRUITING· CTGOV
Publication
Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus.
27 Aug 2026· Annals of the rheumatic diseases· PUBMED
Publication
Evaluating zasocitinib as an oral therapy for moderate to severe plaque psoriasis.
16 Aug 2026· Expert opinion on pharmacotherapy· PUBMED
Publication
Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review.
10 Aug 2026· Immunologic research· PUBMED
Publication
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
7 Aug 2026· Annals of the rheumatic diseases· PUBMED
Publication
Cannabidiol as a Promising Anti-Inflammatory Agent Targeting TYK2: Molecular Docking and Dynamic Simulation Approaches for Therapeutic Applications in Multiple Sclerosis.
30 Jul 2026· Current drug discovery technologies· PUBMED
Publication
Tyrosine kinase 2 inhibition by GL-V9 treats psoriasiform dermatitis via macrophage-helper T-cell modulation.
24 Jul 2026· British journal of pharmacology· PUBMED
Publication
Phosphorylated TYK2 orchestrates the pathogenic program of CD4 + T cells in the development of CNS autoimmunity.
10 Jul 2026· Journal of neuroinflammation· PUBMED
Publication
TYK2 signaling as a molecular bridge between cytokine storm and chronic inflammation: therapeutic implications of deucravacitinib.
3 Jul 2026· Molecular biology reports· PUBMED
Publication
The Role of TYK2 Inhibitors in the Pathogenesis and Treatment of Psoriasis.
1 Jul 2026· The Journal of clinical and aesthetic dermatology· PUBMED
Publication
Targeted therapies against type I interferon and TNF-alpha in cutaneous lupus erythematosus: A systematic review of randomized trials.
30 Jun 2026· Dermatology online journal· PUBMED
Publication
Rethinking TYK2 P1104A: a flawed evolutionary trade-off in tuberculosis?
16 Jun 2026· Frontiers in immunology· PUBMED
Publication
Kirenol, a diterpene active component from Siegesbeckia orientalis, alleviates atopic dermatitis by suppressing TYK2.
3 Jun 2026· International immunopharmacology· PUBMED
Publication
[Successful treatment of lupus erythematosus tumidus (LET) with deucravacitinib in a patient with concomitant plaque psoriasis].
2 Jun 2026· Dermatologie (Heidelberg, Germany)· PUBMED
Publication
Mechanisms of Differential Signal Transduction by Interferon Lambda Receptor 1 Variants.
29 May 2026· Journal of innate immunity· PUBMED
Publication
Discovery of potential covalent TYK2 inhibitors targeting Cys736 for the treatment of psoriasis.
17 May 2026· Bioorganic & medicinal chemistry· PUBMED
Publication
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
16 May 2026· Dermatology and therapy· PUBMED
Publication
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.
12 May 2026· Annals of the rheumatic diseases· PUBMED
Publication
A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel.
8 May 2026· Dermatology online journal· PUBMED
Publication
Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.
1 May 2026· Skin therapy letter· PUBMED
Publication
Long noncoding RNA AFAP1-AS1 aggravates immunotherapy resistance in NSCLC by enhancing JAK2 and TYK2 translation.
24 Apr 2026· Journal of advanced research· PUBMED
Publication
Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis-Eczema Overlap (PsEma): A Retrospective Study.
10 Apr 2026· International journal of dermatology· PUBMED
Publication
Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings.
9 Apr 2026· Dermatology and therapy· PUBMED
Publication
Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.
4 Apr 2026· Dermatology and therapy· PUBMED
Publication
Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction.
25 Mar 2026· Nature communications· PUBMED
Publication
Age-stratified treatment response in rheumatoid arthritis: a systematic review, meta-analysis, and integrated genetic and single-cell evidence implicating IL6R/TYK2 signaling.
18 Mar 2026· Clinical rheumatology· PUBMED
Publication
TYK2 mediates neuroinflammation in Alzheimer's disease brains with TDP-43 pathology.
14 Mar 2026· Nature communications· PUBMED
Publication
Deucravacitinib Inhibits Synovial Fibroblast Activation Via TYK2/STAT3 and PI3K/Akt Signaling Pathway.
11 Mar 2026· Inflammation· PUBMED